This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
Brand Name: Triumeq Other Name(s): ABC/DTG/3TC, abacavir sulfate/dolutegravir sodium/lamivudine Drug Class: Combination Drugs
A fixed-dose combination of dolutegravir plus abacavir/lamivudine proved virologically superior to once-daily ritonavir-boosted atazanavir plus tenofovir/emtricitabine, in a large study of women with HIV.
New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single-tablet regimen of Triumeq.
Paul Sax, M.D., recaps an important study presented at ICAAC 2015, which highlighted 24-week results for patients switching to abacavir/dolutegravir/lamivudine (Triumeq).